Yin-Hua Li-Shi Formula Exerts Anti-Atopic Dermatitis Effects Through Luteolin Targeting AKT/MAPK-IL-6/IL-17 Axis
Journal of Inflammation Research · 2026-03 · Volume 19 · 1-17
DOI: 10.2147/jir.s594212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inflammation Research, 2026-03. Verfasst von Xuemin Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, Peop…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Yin-Hua Li-Shi Formula (YHLS), a medically authorized traditional Chinese medicine (TCM) formulation for atopic dermatitis (AD), has a 30-year clinical application history in China, yet has not had its precise therapeutic mechanisms fully elucidated to date.
Methods
Chemical profiling of YHLS was conducted using high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Network pharmacology predicted YHLS's active ingredients, therapeutic targets, and anti-atopic dermatitis (AD) pathways, with molecular docking validating component-target binding affinity. By intersecting network pharmacology/molecular docking results with mass spectrometry profiles, the key bioactive component was identified. For in vivo validation, an AD-like model was generated via topical MC903 application in C57BL/6 mice. Dermatitis severity, ear thickness, H&E staining, ELISA, RT-qPCR, and Western blot were performed to assess YHLS's efficacy and underlying mechanisms.
Results
Luteolin, the major bioactive component of YHLS targeting AD, was identified by intersecting UPLC-MS/MS metabolite profiles with network pharmacology and molecular docking results. Network pharmacology revealed 102 common targets between YHLS and AD, with PPI/KEGG analyses confirming MAPK1 and AKT1 as core inflammatory targets. Molecular docking assays demonstrated that luteolin binds tightly to MAPK1 (-8.2 kcal/mol) and AKT1 (-9.7 kcal/mol). In MC903-induced AD-like mice, YHLS alleviated symptoms dose-dependently (reduced severity scores, ear thickness, hyperkeratosis, and inflammatory infiltration; all P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, People's Republic of China.
- Central Laboratory, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, People's Republic of China.
- Allergic Dermatoses Clinical Center, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, People's Republic of China.
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People's Republic of China.
ORCID-Profile: Xuemin Wang
Zitieren
APA
Wang, X., Jia, N., Joo, H., Wang, S., Zhang, C., Chen, Q., & Jiang, W. (2026). Yin-Hua Li-Shi Formula Exerts Anti-Atopic Dermatitis Effects Through Luteolin Targeting AKT/MAPK-IL-6/IL-17 Axis. Journal of Inflammation Research, Volume 19, 1-17. https://doi.org/10.2147/jir.s594212
Vancouver
Wang X, Jia N, Joo H, Wang S, Zhang C, Chen Q, et al. Yin-Hua Li-Shi Formula Exerts Anti-Atopic Dermatitis Effects Through Luteolin Targeting AKT/MAPK-IL-6/IL-17 Axis. Journal of Inflammation Research. 2026;Volume 19:1-17. doi:10.2147/jir.s594212
BibTeX
@article{Wang2026,
author = {Wang, Xuemin and Jia, Ning and Joo, Hyewon and Wang, Shuxin and Zhang, Caiyun and Chen, Qilong and Jiang, Wencheng},
title = {Yin-Hua Li-Shi Formula Exerts Anti-Atopic Dermatitis Effects Through Luteolin Targeting AKT/MAPK-IL-6/IL-17 Axis},
journal = {Journal of Inflammation Research},
year = {2026},
volume = {Volume 19},
pages = {1--17},
doi = {10.2147/jir.s594212}
}
EUVIMED